BiotechTube
Retension Pharmaceuticals

Retension Pharmaceuticals

Cambridge, United States· Est.
retensionpharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Retension Pharmaceuticals is a private, clinical-stage biotech targeting the large unmet need in uncontrolled hypertension with its lead candidate, RTN-001. This first-in-class, tissue-targeted PDE5 inhibitor is designed to act preferentially in the central pulmonary vasculature and is currently in Phase 2 trials. The company leverages a seasoned leadership team with deep experience in cardiovascular drug development to advance its pipeline.

CardiovascularHypertension

Technology Platform

Design of tissue-targeted, second-generation PDE5 inhibitors optimized for preferential distribution to the central pulmonary vasculature and aorta to enhance nitric oxide/cGMP signaling for blood pressure control.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The massive, underserved population of patients with uncontrolled hypertension represents a multi-billion dollar market opportunity.
A successful, well-tolerated add-on therapy with a novel mechanism could achieve rapid clinical adoption and significant market share.
Positive Phase 2 data could make the company an attractive partner or acquisition target for larger pharma.

Risk Factors

The company faces high clinical risk as its single asset, RTN-001, must succeed in an ongoing Phase 2 trial and later studies, in a therapeutic area with a history of PDE5 inhibitor failures.
Significant financial risk exists as a private, pre-revenue company with undisclosed funding, reliant on capital raises.
Intense competition in the crowded hypertension market poses commercial risk.

Competitive Landscape

Retension competes in the vast antihypertensive market dominated by cheap generics (ACEi, ARBs, CCBs, diuretics). It faces competition from other novel late-line agents (e.g., aprocitentan, an endothelin receptor antagonist) and would need to demonstrate superior efficacy or tolerability versus other add-on therapies. Its primary differentiation is its tissue-targeted PDE5 inhibition approach.

More companies in United States →